API | pegloticase

pegloticase (krystexxa) Report issue

Biologics Recombinant protein Orphan Drug ^FDA Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH

Active Ingredient History

NOW

Pegloticase is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not tolerated. The drug is administered by infusion intravenously. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
pegloticase

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: No
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$147.8551 - $182.9422

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Organizations (14)

Research & Development (14)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (1)

Gout

Experimental Indications - Clinical Trial Phases 1-4 (11)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 1)

Diabetes Complications (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Diabetic Nephropathies (Phase 2)

Gout ()

Hyperuricemia (Phase 2)

Kidney Transplantation (Phase 4)

Lymphoma (Phase 4)

Neoplasms (Phase 4)

Tumor Lysis Syndrome (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 19
# of Trial Organizations: 14

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue